THD NewsDesk, : Boehringer Ingelheim and Click Therapeutics declared their collaboration for the advancement and commercialisation of a prescription-based digital therapeutic. It utilises neurobehavioral and cognitive mechanisms performed by Click’s proprietary engagement platform.
The aim is to overcome cognitive insufficiencies and impaired social performance in patients with schizophrenia. The two companies will collude to develop a new mobile application. CT-155 connects various clinically curative interventions to support schizophrenia patients to mitigate their performance and further to accomplish accurate clinical results with or without combining pharmaceutical healing options. The collaboration goals for enabling upgraded resources to those who have schizophrenia. It is to provide where there is a curtailment of resources due to impassable psychosocial intervention therapies.
Jan Stefan Scheld, Corporate Senior VP, Therapeutic Area Head CNS, Retinopathies & Emerging Areas, Boehringer Ingelheim said, “At Boehringer Ingelheim, we believe that digital technologies can offer exciting new ways to help patients in need. Therefore, we are pleased to partner with Click Therapeutics on the advancement of a prescription-based digital therapeutic, which will hopefully provide better treatment for patients with schizophrenia.”
Cornelia Dorner-Ciossek, Director, CNS Diseases Research at Boehringer Ingelheim, added, “CT-155 is an excellent addition to our CNS pipeline portfolio. Further, it has the potential to be prescribed together with Boehringer Ingelheim’s schizophrenia pipeline compounds, possibly enhancing the benefit of pharmacotherapy for patients.”
David Benshoof Klein, CEO, Click Therapeutics said, “Partnering with Boehringer Ingelheim allows us to leverage their considerable experience in the clinical development and global commercialisation of new treatment options for neuropsychiatric diseases to improve the efficacy and reach of our digital therapeutic software. We look forward to evaluating CT-155 in a pivotal clinical study, working together with Boehringer Ingelheim to achieve FDA and international regulatory authorisation and to demonstrate the clinical efficacy of this prescription-based digital therapeutic software alone and in combination with traditional pharmaceutical treatments.”
The collaboration agreement deals with research and development activities handled by Click Therapeutics. Boehringer Ingelheim will manage the support to initiate global commercialisation activities.
Click Therapeutics will be funded for research and development activities under the partnership contract. It will also facilitate the development activities which includes clinical, managerial and commercial breakthroughs denoting a deal value of over $500 million. Furthermore, Click Therapeutics shall receive tiered royalties on yearly net sales of CT-155 globally.
Schizophrenia is a severe mental health condition which reconstructs a person’s understanding of reality. It impacts how a person thinks, behaves and feels. Patients with schizophrenia can remain functionally diminished due to negatively treated symptoms. It includes cognitive deficiencies and restricted social awareness. Schizophrenia is one of the 15 leading causes of disability globally, including, nearly half of all patients manifesting either mental and behavioural health disorders.